NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.420
+0.140 (10.94%)
At close: Nov 4, 2026, 4:00 PM EST
1.350
-0.070 (-4.93%)
After-hours: Nov 4, 2026, 7:22 PM EST
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes NeuroSense Therapeutics the 38,803rd largest employer in the world and 5,642nd in the United States.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
2.63M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| HCW Biologics | 35 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| VivoSim Labs | 15 |
| Dermata Therapeutics | 9 |
| Revelation Biosciences | 9 |
| Eocene | 6 |
NRSN News
- 2 days ago - NeuroSense downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 days ago - NeuroSense downgraded at H.C. Wainwright on extended PrimeC timelines - TheFly
- 2 days ago - NeuroSense adds new data to its Canadian submission of ALS candidate - TheFly
- 2 days ago - NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data - PRNewsWire
- 6 days ago - NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 - PRNewsWire
- 16 days ago - NeuroSense files patent in USPTO covering methods to treat TBI - TheFly
- 16 days ago - NeuroSense Files U.S. Patent Application for Traumatic Brain Injury - PRNewsWire
- 22 days ago - NeuroSense secures Nasdaq hearing date as PrimeC approaches milestones - TheFly